Crescendo Biologics to present preclinical data on its lead Humabody® candidate, CB307, at the Cell Engager Therapeutics Summit 2019

Crescendo Biologics to present preclinical data on its lead Humabody® candidate, CB307, at the Cell Engager Therapeutics Summit 2019

View PDF

CB307: A novel T-cell costimulatory Humabody® VH therapeutic for PSMA-positive tumors (PEGS 2019 poster)

CB307: A novel T-cell costimulatory Humabody® VH therapeutic for PSMA-positive tumors (PEGS 2019 poster)

View Poster

Crescendo Biologics wins in “Life Science Innovation” category at the Business Weekly Awards 2019

Crescendo Biologics wins in “Life Science Innovation” category at the Business Weekly Awards 2019

View PDF

Multifunctional Humabody® biologics for immune-oncology, based on in vivo matured fully human VH domains

Multifunctional Humabody® biologics for immune-oncology, based on in vivo matured fully human VH
domains (PEGS 2018 poster)

View Poster